Medtronic Diabetes

What Medtronic Diabetes does

Medtronic Diabetes, operating as Medtronic MiniMed, Inc., is a medical device company specializing in automated insulin delivery (AID) systems and continuous glucose monitoring (CGM) for diabetes management. The company is the only manufacturer producing both insulin-delivery pumps and CGMs, enabling fully integrated closed-loop systems through its proprietary SmartGuard technology, which automatically adjusts insulin delivery every 5 minutes based on real-time CGM readings and can predict and prevent hypoglycemic events. Its product portfolio includes the flagship MiniMed 780G system (advanced AID pump with SmartGuard), MiniMed Flex (compact AID pump), MiniMed Go (smart MDI system integrating InPen smart insulin pen with Abbott CGM sensors), and CGM sensors including Simplera Sync, Guardian 4, and Abbott's Instinct sensor. The company also deploys the DreaMed AI-powered algorithm for optimized insulin delivery calculations.

The business generates revenue through hardware sales (insulin pumps, CGM sensors) and recurring subscription-like auto-supply programs (infusion sets, replacement sensors). Medtronic's Diabetes division generates approximately $2.5–2.8 billion in annual revenue, ranking third globally among diabetes technology companies behind Abbott ($5.8B) and Dexcom ($3.6B). The company distributes through direct-to-consumer e-commerce (diabetes.shop), healthcare provider prescriptions, Medicare/insurance coverage pathways, and phone support (1-800-MINIMED), handling insurance verification internally.

Medtronic Diabetes operates as a division of Medtronic plc (NYSE: MDT), with the diabetes business headquartered in Northridge, California. In May 2025, Medtronic announced the spin-off of the diabetes business into a standalone direct-to-consumer company valued at $2.8 billion. The company serves primarily Type 1 diabetes patients, with recent FDA clearances expanding into insulin-requiring Type 2 diabetes patients and pediatric populations (ages 2+). Recent strategic moves include a partnership with Abbott for exclusive CGM integration, multiple FDA clearances, and Medicare coverage expansion for the MiniMed 780G system.

Name

Medtronic Diabetes

Legal name

Medtronic MiniMed, Inc.

Website

https://medtronicdiabetes.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Medtronic Diabetes (Medtronic MiniMed, Inc.) designs and sells automated insulin delivery systems and continuous glucose monitors—including MiniMed 780G, Flex, Go, and Simplera sensors—for Type 1 and insulin-requiring Type 2 diabetes patients, generating approximately $2.5–2.8 billion in annual revenue.

Ownership category

akta.pro rank

Product category

Insulin Pumps and Continuous Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Patch Pumps & Wearable Insulin Delivery (HLAHAHAC), Insulin Pumps (Tubed) (HLAHAHAB), Smart Insulin Pens & Connected Pen Caps (HLAHAHAD), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Insulin pump systems
• Continuous glucose monitoring
• Automated insulin delivery
• Diabetes management devices
• Smart insulin pen

Headquarters

HQ city

Northridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Insulin Delivery Devices: Sale of insulin pumps including MiniMed 780G, MiniMed Flex, and related accessories. Medtronic's Diabetes division generates approximately $2.5B in annual revenue, making it the third-largest diabetes technology company.
2. CGM Sensors and Accessories: Continuous glucose monitoring sensors including Simplera Sync, Guardian 4, and compatibility with Abbott's Instinct sensor. Ongoing consumable revenue from sensor replacements.
3. Infusion Sets and Supplies: Ongoing supplies including infusion sets (7-day wear), sensors, and other diabetes management consumables delivered through subscription-like auto-supply programs.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Medtronic Diabetes (operating as MiniMed) designs, manufactures, and sells automated insulin delivery systems, continuous glucose monitoring sensors, and smart insulin pens for people with Type 1 and insulin-requiring Type 2 diabetes. Its flagship products include the MiniMed 780G and MiniMed Flex insulin pumps featuring SmartGuard technology, alongside the MiniMed Go smart MDI system integrating Abbott CGM sensors with the InPen smart insulin pen.

Product overview

Medtronic Diabetes (operating as MiniMed) offers a comprehensive insulin delivery and glucose monitoring ecosystem. The portfolio centers on automated insulin delivery (AID) systems including the MiniMed 780G and MiniMed Flex insulin pumps, both featuring SmartGuard technology that automatically adjusts insulin delivery based on real-time CGM data. For multiple daily injection (MDI) users, MiniMed Go integrates Abbott's CGM sensors with the InPen smart insulin pen via a mobile app. The company supports multiple CGM sensors (Simplera Sync, Guardian 4, and Abbott's Instinct) across its platforms, providing patients and healthcare providers flexibility in diabetes management. Medtronic's diabetes business generates approximately $2.8 billion in annual revenue and is structured as a standalone direct-to-consumer company following a spinoff from Medtronic plc.

Differentiator

Problem solved

Functional benefit

Brands

• MiniMed 780G: Advanced automated insulin delivery system with SmartGuard technology that automatically adjusts insulin delivery every 5 minutes based on CGM readings.
• MiniMed Go
• MiniMed Flex
• InPen
• Simplera Sync
• Guardian 4

Products and services

• MiniMed 780G System Advanced automated insulin delivery system that automatically corrects sugar levels every 5 minutes based on real-time CGM readings to optimize Time in Range. Features SmartGuard technology, a 15-day sensor, and a 7-day infusion set. FDA-cleared for Type 1 diabetes patients ages 7 and older and Type 2 diabetes patients ages 18 and older requiring insulin.
• MiniMed Flex System

Quantifiable outcome

• Time in Range optimization through automated insulin adjustments every 5 minutes
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature7 records

Partnerships

One partnership is on record.

• AbbottcoreTechnology or Integration · 22 May 2025Medtronic and Abbott announced a strategic partnership where Abbott will develop a continuous glucose monitor exclusively compatible with Medtronic's insulin pump devices. The deal addresses Medtronic's longstanding weakness in CGM technology, with analysts projecting it could boost Medtronic's diabetes business revenues long-term by providing patients with more integrated options for diabetes management. Medtronic also submitted an FDA clearance application for pairing its pumps with Abbott FreeStyle Libre CGM technology. The MiniMed Go system is already cleared for use with Abbott's Instinct CGM sensor.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• LifeScan: LifeScan (OneTouch) is a blood glucose monitoring company now owned by Platinum Equity. Adjacent peer in the diabetes monitoring space; while it focuses on BGM rather than CGM and pumps, it serves the same diabetes patient population with overlapping chronic-condition management offerings.
• Roche Diabetes Care: Roche's Diabetes Care division produces Accu-Chek insulin pumps, BGMs, and digital diabetes management tools under a broader diagnostics conglomerate. Overlaps with Medtronic in insulin pumps and glucose monitoring, but with a smaller share and broader healthcare portfolio focus.
• Novo Nordisk: Novo Nordisk is the global leader in insulin manufacturing and increasingly in GLP-1 therapies (Ozempic, Wegovy). Indirect peer/partner given its insulin pen portfolio competes with Medtronic's InPen smart pen integrations, and its GLP-1 drugs could reduce future insulin pump demand.

Direct peers

• Insulet Corporation: Insulet's Omnipod is a tubeless, wearable patch insulin pump that has been gaining share against Medtronic's tubed MiniMed systems, including via AID integration with Dexcom CGMs. Direct pump-market competitor targeting the same Type 1 patient population.
• Dexcom: Dexcom is a leading CGM manufacturer with $3.6B in revenue, the closest direct competitor to Medtronic in diabetes technology. Dexcom partners with pump makers including Insulet (Omnipod) and Tandem, competing with Medtronic's integrated pump + CGM stack and driving the need for Medtronic's Abbott partnership.
• Tandem Diabetes Care: Tandem manufactures the t:slim X2 insulin pump with Control-IQ hybrid closed-loop algorithm integrating Dexcom CGMs. A direct competitor to Medtronic's MiniMed 780G in the AID segment, particularly popular with Type 1 patients seeking smaller form factors.
• Abbott Diabetes Care: Abbott's Diabetes Care division ($5.8B revenue, the largest in diabetes tech) makes FreeStyle Libre CGMs and is Medtronic's exclusive CGM partner for the Instinct sensor. Direct overlap with Medtronic's CGM line and competing for the same insulin-requiring patient population.

Regional players

• Ypsomed: Ypsomed manufactures the mylife YpsoPump insulin pump and offers an AID system (mylife Loop) integrated with Dexcom CGMs, primarily serving European markets. Comparable to Medtronic's pump business in functionality and target patient base, but with limited US presence.

Emerging players

• Bigfoot Biomedical: Bigfoot Unity was a connected insulin pen system with CGM integration, directly comparable to Medtronic's MiniMed Go / InPen offering. An emerging player focused on smart MDI users rather than pump users, addressing an adjacent segment with overlapping technology.
• Beta Bionics: Beta Bionics makes the iLet bionic pancreas, an automated insulin delivery system that requires no carb counting. Emerging competitor in the AID segment addressing similar Type 1 diabetes patients as Medtronic's MiniMed 780G with a differentiated algorithmic approach.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MDT_Diabetes
• YouTubeyoutube.com/@minimed_US
• Facebookfacebook.com/minimed
• LinkedInlinkedin.com/company/medtronic-mini-med
• Instagraminstagram.com/minimed

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medtronic Diabetes